PSORIASIS

Our lead Lecinoxoid-based compound, VB-201, has been designed as an oral agent for the control of chronic inflammatory disorders. Initially, we are developing it for psoriasis and ulcerative colitis. 

VBL has recently completed an exploratory double-blind, placebo-controlled Phase 2 trial evaluating safety and establishing dosage of VB-201 in patients with psoriasis.

We are currently conducting a Phase 2 clinical trial of VB-201 in patients with moderate to severe psoriasis, for which we have completed enrollment. This is a  multi-center, randomized, double-blind trial to evaluate the efficacy and safety of oral VB-201 in patients with moderate to severe plaque psoriasis. The trial is conducted in Europe and Israel. In this trial we increased the exposure by doubling the dose (160mg daily) and the duration of the treatment compared to the previous exploratory phase 2 trial.

 

 For more information please click here.